ASSAY OF THE ANTI-OESTROGENIC EFFECTS OF PROGESTAGENS IN WOMEN

Abstract
An assay to determine the anti-estrogenic potency of progestagens in women is described. The progressive increase in endometrial glandular suppression with increasing doses of progestagens is the basis of the assay. Norethindrone (estrogen free) is 3 times as potent as chlormadinone acetate with a 95% confidence limit of 2.3 to 4.0. This is in contrast to the greater secretory potency of chlormadinone acetate. It is suggested that the anti-estrogenic action of progestagens is of some importance in the selection of compounds for contraceptives of the combined progestagen-estrogen, and of great importance for those of the continuous low dose progestagen types. This property may also be desirable in the treatment of both endometrial hyperplasia and adenocarcinoma.

This publication has 3 references indexed in Scilit: